StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac by Year

Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac: $6,380M in FY2025, up 17.0% from a year earlier. That is the highest of the 9 years on record here.

Latest, FY2025
6,380
Period ended Dec 31, 2025
Change on a year earlier
+17.0%
5,451 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Vyndaqel family (e) | 6,380 | 5,451 | 17% | 16% | 3,834 | 3,547 | 8% | 2,546 | 1,904 | 34% | 30%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 20256,380+17.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20245,451+64.1%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20233,321+304.5%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022821+43.5%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021Dec 31, 2021572+76.5%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020Dec 31, 2020324+113.2%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019Dec 31, 2019152+65.2%Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2018Dec 31, 201892-25.8%Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2017Dec 31, 2017124–Form 10-K (filed 2020-02-27) ↗

Breakdown

What makes up vyndaqel Family (Vyndaqel / Vyndamax / Vynmac

Cite this data

StockData. (2026). Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac ($M), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/vyndaqel-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.